"We observed a correlation between anti-spike (S) immunoglobulin G (IgG) levels, length of hospitalization and clinical parameters associated with worse clinical progression. Although high anti-S IgG levels correlated with worse disease severity, such correlation was time dependent."

"...high anti-S IgG levels correlated with worse disease severity, such correlation was time dependent. Deceased patients did not have higher overall humoral response than discharged patients. However, they mounted a robust, yet delayed, response, measured by anti-S, anti-receptor-binding domain IgG and neutralizing antibody levels compared to survivors."

"Delayed seroconversion kinetics correlated with impaired viral control in deceased patients."

"Finally, although sera from 85% of patients displayed some neutralization capacity during their disease course, NAb generation before 14 d of disease onset emerged as a key factor for recovery."

"These data indicate that COVID-19 mortality does not correlate with the cross-sectional antiviral antibody levels per se but, rather, with the delayed kinetics of NAb production."

所以，台灣疫苗 EUA 審核標準只分析中和抗體濃度，其實是不夠的；有各種科學理由可以駁斥「免疫橋接」的現行手法，而現在又多了「何時產生抗體」這個重要要素。